Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Auto stocks in demand today
Mon, 29 Dec Closing

After starting the day on a firm note, Indian share markets pared some of their gains and trended lower in the post-noon trading session, albeit closing the day on a firm note. The BSE-Sensex closed up by 154 points while the NSE-Nifty closed higher by 46 points. Both midcap and small cap stocks were in demand. BSE Mid Cap closed higher by 0.87% and BSE Small Cap index up by 0.53%. Barring banking stocks, most of the sectoral indices closed in green with auto stocks being the most favoured.

As regards to the global markets, the Asian pack closed mixed today with Hong Kong leading the gains. The rupee was trading at Rs 61.65 to the dollar at the time of writing.

Most of the Indian pharma stocks closed the day on a positive note with the leadings gainers being Orchid Chemicals and Wockhardt. As per a leading business daily, Glenmark Pharmaceuticals is set to out-license its molecule, GRC 17536 for pain management. The company is in talks with some multinational companies and the deal is likely in next few months. The molecule has successfully completed phase-II trials on 138 patients in Europe and India. In past 10 years, the company has signed approx 7 out-licensing deals. Post out-licensing the drug, Glenmark gets out-licensing payment and subsequent milestone payments on the successful completion of trials. Glenmark's out-licensed drug Croflemer was approved by USFDA in 2013. Company has been quite active in developing and out-licensing its molecules.

Majority of telecom stocks have closed the day in the green led by Tata Teleservices and Idea Cellular. As per a leading business daily, telecom companies such as Idea Cellular are eagerly awaiting announcement on reserve price for spectrum auction. In an interview, Himanshu Kapania, the Managing Director of the company stated that he expects the upcoming auction for spectrum to be anywhere between 8 and 10 times of earlier prices, which will ultimately mean that the consumers will have to bear the costs. The current spectrum capacity of Idea stands at 253 MHz, of which 60 MHz is coming up for renewals. Most of the spectrum that will be up for renewal is from the 900 MHz band. The company had expanded its spectrum capacity in Feb this year.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto stocks in demand today". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.